THE CONTROL OF EXCESSIVE EFFECT BY ANTICOAGULANTS
Authors: I F DUFF, J R GAMBLE, P W WILLIS, P E HODGSON, W S WILSON, J A POLHEMUS
Journal: Annals of Internal Medicine (1955)

Article1 November 1955THE CONTROL OF EXCESSIVE EFFECT BY ANTICOAGULANTSIVAN F. DUFF, M.D., JOHN R. GAMBLE, M.D., PARK W. WILLIS III, M.D., PAUL E. HODGSON, M.D., WILLIAM S. WILSON, M.D., JOSIAH A. POLHEMUS, M.D.IVAN F. DUFF, M.D., JOHN R. GAMBLE, M.D., PARK W. WILLIS III, M.D., PAUL E. HODGSON, M.D., WILLIAM S. WILSON, M.D., JOSIAH A. POLHEMUS, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-43-5-955 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptINTRODUCTIONThe decision to administer anticoagulant drugs should imply familiarity with the indisputable complication of hemorrhage which they evoke. This report is concerned with factors which are important in the control of excessive effect by these potent drugs.AVAILABLE ANTICOAGULANTS AND IMPORTANT PHARMACOLOGIC PROPERTIESA few years ago selection of an anticoagulant was not a problem, for the choice was limited to Dicumarol or heparin. In the search for more satisfactory preparations several derivatives have become available, and their number is now sufficiently large to be confusing. Pertinent summaries are to be found elsewhere1-5regarding the details of administration and...Bibliography1. Wright IS: An evaluation of anticoagulant therapy, Am. J. Med. 14: 720, 1953. CrossrefMedlineGoogle Scholar2. CoonDuffHodgsonDennis WWIFPEEW: Therapeutic evaluation of a new anticoagulant, phenylindaridione, Ann. Surg. 138: 467, 1953. CrossrefMedlineGoogle Scholar3. PascaleOlwin LRJH: Clinical experience with a new anticoagulant, Dipaxin (2-diphenylacetyl-1, 3-indandione), Circulation 9: 230, 1954. CrossrefMedlineGoogle Scholar4. Matis P: Marcumar, a new superdicumarol, Ärztl. Forsch. 7: 298, 1953. Google Scholar5. Shapiro S: Warfarin sodium derivatives: (Coumadin Sodium); an intravenous hypoprothrombinemia-inducing agent, Angiology 4: 380, 1953. CrossrefMedlineGoogle Scholar6. OwrenAas PAK: The control of Dicumarol therapy and the quantitative determination of prothrombin and proconvertin, Scandinav. J. Clin. and Lab. Invest. 3: 201, 1951. CrossrefMedlineGoogle Scholar7. Owren PA: A quantitative one-stage method for the assay of prothrombin, Scandinav. J. Clin. and Lab. Invest. 1: 81, 1949. CrossrefMedlineGoogle Scholar8. Owren PA: Prothrombin and accessory factors, Am. J. Med. 14: 201, 1953. CrossrefMedlineGoogle Scholar9. WalkerHunter WRB: Action of coumarin anticoagulants on a possible new serum clotting factor, Nature, London 173: 1192, 1954. CrossrefMedlineGoogle Scholar10. Seegers WH: Nature of the blood coagulation mechanisms, in Thrombosis and embolism. I. International Conference, Basel, 1954, Benno Schwabe & Co., Basel, p. 31. Google Scholar11. Adams WR: Treatment of cardiovascular diseases with anticoagulants, Postgrad. Med. 17: 1, 1955. CrossrefMedlineGoogle Scholar12. ManchesterRabkin BB: The control of Dicumarol therapy in myocardial infarction by a simple blood prothrombin test, Circulation 10: 691, 1954. CrossrefMedlineGoogle Scholar13. Quick AJ: Physiology and pathology of hemostasis, 1951, Lea & Febiger, Philadelphia. Google Scholar14. ZiffrenOwenHoffmanSmith SECAGRHP: A simple bedside test for control of vitamin K therapy, Am. J. Clin. Path. 10: 13, 1940. CrossrefGoogle Scholar15. Link KP: The anticoagulant from spoiled sweet clover hay, in Harvey Lecture Series (1943-1944), 1944, Science Press Printing Co., Lancaster, Pa. Vol. 39, p. 162. Google Scholar16. Shapiro S: Long-term anticoagulant therapy, M. Clin. North America 37: 659 (May) 1953. CrossrefGoogle Scholar17. Olwin JH: Significance of different methods for prothrombin estimation and their relative values, Surg., Gynec. and Obst. 90: 423, 1950. Google Scholar18. Lehmann J: Determination of prothrombin in the clinic, Acta med. Scandinav. Supp. 287: 48, 1953-54. Google Scholar19. WareStragnell AGR: Improved one-stage prothrombin method, Am. J. Clin. Path. 22: 791, 1952. CrossrefMedlineGoogle Scholar20. WarnerBrinkhousSmith EDKMHP: A quantitative study on blood clotting; prothrombin fluctuations under experimental conditions, Am. J. Physiol. 114: 667, 1936. CrossrefGoogle Scholar21. WareSeegers AGWH: Two-stage procedure for the quantitative determination of prothrombin concentration, Am. J. Clin. Path. 19: 471, 1949. CrossrefMedlineGoogle Scholar22. Olwin JH: The one-stage and two-stage prothrombin methods in the control of Dicumarol therapy with remarks on Ac-globulin, J. Lab. and Clin. Med. 34: 806, 1949. MedlineGoogle Scholar23. HurnBarkerMann MNWFD: Variations in prothrombin and antithrombin following administration of Dicumarol, Am. J. Clin. Path. 17: 712, 1947. CrossrefMedlineGoogle Scholar24. AllenHinesKvaleBarker EVEAWFNW: The use of Dicumarol as an anticoagulant: experience in 2,307 cases, Ann. Int. Med. 27: 371, 1947. LinkGoogle Scholar25. WrightMarpleBeck ESCDDF: Myocardial infarction, its clinical manifestation and treatment with anticoagulants, 1954, Grune and Stratton, New York, p. 464. Google Scholar26. BrambelHunterFitzpatrick CEREVd: Prophylactic use of anticoagulants in puerperal period (Dicumarol, heparin, and Link compound 63), Bull. School Med. Univ. Maryland 35: 91, 1950. MedlineGoogle Scholar27. GriffithStragnellLevinsonMooreWare GCRDCFJAG: A study of the beneficial effects of anticoagulant therapy in congestive heart failure, Ann. Int. Med. 37: 867, 1952. LinkGoogle Scholar28. Alexander B: Coagulation, hemorrhage and thrombosis, New England J. Med. 253: 432, 1955. CrossrefGoogle Scholar29. SmithSchelling FJV: A clinical comparison of laboratory methods used in controlling anticoagulant therapy, in Thrombosis and embolism. I. International Conference, Basel, 1954, Benno Schwabe and Co., Basel, p. 31. Google Scholar30. BresnickSelverstoneRapoportCheskeyHultgrenSise ELABKHNHS: Experiences with Dicumarol in acute myocardial infarction, New England J. Med. 243: 806, 1950. CrossrefMedlineGoogle Scholar31. GambleDennisCoonHodgsonWillisMaCrisDuff JREWWWPPWJAIF: Clinical comparison of vitamin K1 and water-soluble vitamin K, Arch. Int. Med. 95: 52, 1955. CrossrefGoogle Scholar32. DamGeillLungSondergaard HTEE: Investigation of the effect of vitamin K1 and vitamin K derivatives (Menadione preparations) in Dicumarol poisoning, Ugesk. f. laeger 116: 291, 1954. MedlineGoogle Scholar33. Toohey M: Vitamin K in anticoagulant therapy, Brit. M. J. 1: 1020, 1954. CrossrefMedlineGoogle Scholar34. RickettsWaltonvan LeuvenBirbeckBrownKennedyBurt CRKWBDAAACCC: Therapeutic trial of the synthetic heparin analogue, dextran sulphate, Lancet 2: 1004, 1953. CrossrefGoogle Scholar35. LeeWhite RIPD: A clinical study of the coagulation of blood, Am. J. M. Sc. 145: 495, 1913. CrossrefGoogle Scholar36. JewellPilkingtonRobinson PTB: Heparin and ethyl biscoumacetate in prevention of experimental venous thrombosis, Brit. M. J. 1: 1013, 1954. CrossrefMedlineGoogle Scholar37. HauchBarker EWNW: Experiences with heparin: comparative effects of intravenous and subcutaneous administration in the same individuals, J. Lab. and Clin. Med. 38: 550, 1951. MedlineGoogle Scholar38. BestCowanMacLean CHCDL: Heparin and formation of white thrombi, J. Physiol. 92: 24, 1938. CrossrefGoogle Scholar39. DuffLinmanBirch IFJWR: Administration of heparin, Surg., Gynec. and Obst. 93: 343, 1951. MedlineGoogle Scholar40. ArtzPulaski CPEJ: The treatment of venous thrombosis with heparin, Angiology 4: 321, 1953. CrossrefMedlineGoogle Scholar41. HauchCarryerMathieson EWHMDR: Hypersensitivity to heparin: report of 3 cases, Proc. Staff Meet., Mayo Clin. 27: 163, 1952. MedlineGoogle Scholar42. Bruzelius S: Dicumarin in clinical use: studies on its prophylactic and therapeutic value in the treatment of thromboembolism, Acta chir. Scandinav. (supp. 100) 92: 1, 1945. Google Scholar43. Wessler S: Studies in intravascular coagulation. II. Comparison of effect of Dicumarol and heparin on clot formation in isolated venous segments, J. Clin. Investigation 32: 650, 1953. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: IVAN F. DUFF, M.D.; JOHN R. GAMBLE, M.D.; PARK W. WILLISIII, M.D.; PAUL E. HODGSON, M.D.; WILLIAM S. WILSON, M.D.; JOSIAH A. POLHEMUS, M.D.*From the Symposium on Acute Myocardial Infarction, presented at the Thirty-sixth Annual Session of The American College of Physicians, Philadelphia, Pennsylvania, April 26, 1955.From the Departments of Internal Medicine and Surgery of the University of Michigan Medical School.†This study was assisted by grants-in-aid from the Michigan Heart Association and the H. R. Rackham School of Graduate Studies of the University of Michigan. Financial support has also been received from the Upjohn Pharmaceutical Company. Supplies of Mephyton were made available through the courtesy of Merck and Company, Inc. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byEffects of the anticoagulant diphenadione on suckling calvesBleeding during oral anticoagulant therapyEditorialUse of anticoagulant and fibrinolytic agentsKrankheiten der GefäßeA comparative study of four prothrombinopenic anticoagulant drugsThe use of anticoagulants for thrombophlebitis during pregnancyThe Treatment of Cerebrovascular AccidentTHE EFFECTIVENESS OF AN ORAL VITAMIN K1 IN CONTROLLING EXCESSIVE HYPOPROTHROMBINEMIA DURING ANTICOAGULANT THERAPY*STUART W. COSGRIFF, M.D. 1 November 1955Volume 43, Issue 5 Page: 955-978 Keywords Anticoagulant therapy Anticoagulants Drugs Graduate medical education Heart Hemorrhage Hemostatics Heparin Longitudinal studies Surgery ePublished: 1 December 2008 Issue Published: 1 November 1955 PDF downloadLoading ...